Flunixin meglumine_product_DataBase

Bioactivity	Flunixin meglumine is a cyclooxygenase (COX) inhibitor with IC50 values of 0.55 and 3.24 μM for COX-1 and COX-2, respectively. Flunixin meglumine shows anti-inflammatory effects[1][2].
Invitro	flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide (LPS)-induced activity of inducible nitric oxide synthase (iNOS) in RAW 264.7 murine macrophages[2].flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide-induced activation of nuclear factor kappa B (NfκB) in RAW 264.7 murine macrophages[2]. Cell Viability Assay[2] Cell Line:
In Vivo	Flunixin meglumine (intravenous injection; 1.1 mg/kg; once) treatment inhibits the formation of exudate PGE2 and serum TXB2[1]. Animal Model:
Name	Flunixin meglumine
CAS	42461-84-7
Formula	C21H28F3N3O7
Molar Mass	491.46
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Z Cheng, et al. Measurement of cyclooxygenase inhibition in vivo: a study of two non-steroidal anti-inflammatory drugs in sheep. Inflammation. 1998 Aug;22(4):353-66. [2]. Clare E Bryant, et al. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B. Am J Vet Res. 2003 Feb;64(2):211-5.

PeptideDB